A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m 2 preceded by escalating doses of docetaxel 60 mg/m 2 (75, 90, 100 mg/m 2 ) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m 2 with oxaliplatin 130 mg/m 2 .